The present proposal is designed to examine the effects of a new medication, Acamprosate on two central features of alcohol dependence: withdrawal and loss of control over drinking. Acamprosate has been approved as a treatment for alcohol dependence in several European countries based on evidence indicating a significant improvement in continuous abstinence rates following acamprosate treatment. However, although acamprosate attenuates alcohol drinking in rodents there is minimal information regarding alcohol drinking in humans. Subjects will be randomly assigned to receive either one of two doses (1500 or 3000 mg/day) of acamprosate, or placebo for 13 days. During the first seven outpatient days drinking behavior will be monitored. This will be followed by a four-day inpatient period when withdrawal will be monitored, followed by a fifth inpatient day when subjects will be exposed to an alcohol self-administration paradigm, during which deprivation-induced alcohol consumption behavior will be monitored.
The specific aims of this proposal are: 1) To examine whether pretreatment with two doses of acamprosate, or placebo, for seven days prior to abstinence initiation attenuates the intensity of acute alcohol withdrawal. We hypothesize that acamprosate will dose dependently reduce the intensity of withdrawal-induced changes in neuroendocrine, physiological, subjective and cognitive responses; 2) To determine whether acamprosate attenuates responses to a fixed low dose of alcohol (0.03 gm/kg) following a period of alcohol deprivation. We hypothesize that acamprosate will reduce the stimulatory effects of, and craving for, alcohol; 3) To determine whether acamprosate dose dependently reduces alcohol self-administration following an initial priming dose. Better characterization of these effects will be important for determining the optimal sequencing and timing of pharmacotherapies such as acamprosate for alcohol dependence, and for increasing overall success rates of achieving and maintaining abstinence.

Agency
National Institute of Health (NIH)
Institute
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Type
Specialized Center (P50)
Project #
3P50AA003510-23S2
Application #
6354569
Study Section
Project Start
2000-09-20
Project End
2000-11-30
Budget Start
1998-10-01
Budget End
1999-09-30
Support Year
23
Fiscal Year
2000
Total Cost
$184,557
Indirect Cost
Name
University of Connecticut
Department
Type
DUNS #
City
Farmington
State
CT
Country
United States
Zip Code
06030
Rash, Carla J; Petry, Nancy M; Alessi, Sheila M et al. (2018) Monitoring Alcohol Use in Heavy Drinking Soup Kitchen Attendees. Alcohol :
Rash, Carla J; Petry, Nancy M; Alessi, Sheila M (2018) A randomized trial of contingency management for smoking cessation in the homeless. Psychol Addict Behav 32:141-148
Rash, Carla J; Alessi, Sheila M; Petry, Nancy M (2017) Substance Abuse Treatment Patients in Housing Programs Respond to Contingency Management Interventions. J Subst Abuse Treat 72:97-102
Lieberman, Richard; Armeli, Stephen; Scott, Denise M et al. (2016) FKBP5 genotype interacts with early life trauma to predict heavy drinking in college students. Am J Med Genet B Neuropsychiatr Genet 171:879-87
Rash, Carla J; Petry, Nancy M (2016) Gambling Disorder in the DSM-5: Opportunities to Improve Diagnosis and Treatment Especially in Substance Use and Homeless Populations. Curr Addict Rep 3:249-253
Meredith, Steven E; Alessi, Sheila M; Petry, Nancy M (2015) Smartphone applications to reduce alcohol consumption and help patients with alcohol use disorder: a state-of-the-art review. Adv Health Care Technol 1:47-54
Armeli, Stephen; Sullivan, Tami P; Tennen, Howard (2015) Drinking to Cope Motivation as a Prospective Predictor of Negative Affect. J Stud Alcohol Drugs 76:578-84
Ohannessian, Christine McCauley; Finan, Laura J; Schulz, Jessica et al. (2015) A Long-Term Longitudinal Examination of the Effect of Early Onset of Alcohol and Drug Use on Later Alcohol Abuse. Subst Abus 36:440-4
Kranzler, Henry R; Covault, Jonathan; Feinn, Richard et al. (2014) Topiramate treatment for heavy drinkers: moderation by a GRIK1 polymorphism. Am J Psychiatry 171:445-52
Andrade, Leonardo F; Petry, Nancy M (2014) White problem gamblers discount delayed rewards less steeply than their African American and Hispanic counterparts. Psychol Addict Behav 28:599-606

Showing the most recent 10 out of 407 publications